Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer

Appoints CNS specialist and establishes US presence with new office in Cambridge, MA

Lausanne, SWITZERLAND and Cambridge, MA, USA, December 6, 2018 – Asceneuron, an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative diseases, announced today the appointment of Thomas C. Wessel, MD, PhD, as Chief Medical Officer. Tom has over 20 years of experience in the biopharmaceutical industry and will be responsible for progressing the development of Asceneuron’s lead program ASN120290 and a pipeline of novel small molecules through the clinic. Tom will be based at Asceneuron’s new offices in Cambridge, Massachusetts, where he will lead all regulatory and clinical development activities as part of the company’s further expansion in the United States.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH